* Aetna adds Sarepta's DMD drug Exondys 51 to its coverage effective Novemeber 1,2016 Source (http://aet.na/2eR7liT)
(The following statement was released by the rating agency) CHICAGO, October 27 (Fitch) Fitch Ratings has assigned an 'A' rating to Merck & Co., Inc.'s (MRK/Merck) euro notes offering. A complete list of ratings follows at the end of this press release. KEY RATING DRIVERS The company's 'A' rating reflects the following: --Recently introduced therapies, an advancing pipeline and manageable patent expiries should support intermediate- to long-term growth. --Fitch believes that Merck will pursu
Oct 27 Bristol-Myers Squibb Co, whose high-profile Opdivo immunotherapy failed an important lung-cancer trial last summer, sharply raised its 2016 profit forecast after strong quarterly sales of other leading medicines.
* Reports H1 revenue of 1.5 million euros ($1.6 million) versus 1.3 million euros a year ago
* Cash & cash equivalents and liquid investments of 12.3 million euros ($13.4 million) as at Sept. 30, 2016, in line with company's expectations Source text: http://bit.ly/2eVNVHR Further company coverage: ($1 = 0.9181 euros) (Gdynia Newsroom)
NEW DELHI/MUMBAI Tata Sons accused its former chairman, Cyrus Mistry, of making "unsubstantiated claims and malicious allegations" against the Indian conglomerate as the gloves came off in a bitter and highly public row over his sacking earlier this week. | Video